Trials / Recruiting
RecruitingNCT07020819
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of a Single Dose of Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (GBS) (FORWARD Study)
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Annexon, Inc. · Industry
- Sex
- All
- Age
- 12 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tanruprubart | Solution for IV infusion. |
Timeline
- Start date
- 2025-09-12
- Primary completion
- 2026-12-31
- Completion
- 2028-06-30
- First posted
- 2025-06-13
- Last updated
- 2026-02-20
Locations
9 sites across 2 countries: United States, Denmark
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07020819. Inclusion in this directory is not an endorsement.